0001079973-24-000043.txt : 20240109 0001079973-24-000043.hdr.sgml : 20240109 20240109163013 ACCESSION NUMBER: 0001079973-24-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240104 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPGEN INC CENTRAL INDEX KEY: 0001293818 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 061614015 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37367 FILM NUMBER: 24523627 BUSINESS ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-869-9683 MAIL ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 opgen_8k.htm FORM 8-K
false 0001293818 0001293818 2024-01-04 2024-01-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

  January 4, 2024
Date of Report (date of earliest event reported)

_________________

OpGen, Inc.

(Exact name of Registrant as specified in its charter)

_________________

Delaware

(State or other jurisdiction of incorporation or organization)

  

001-37367

(Commission

File Number)

  

06-1614015

(I.R.S. Employer
Identification Number)

9717 Key West Ave, Suite 100
Rockville, MD 20850
(Address of principal executive offices)(Zip code)

(240) 813-1260
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

_________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock OPGN The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

In light of OpGen, Inc.’s (the “Company”) focus on pursuing strategic alternatives and recent actions taken by its Board of Directors (the “Board”) to reduce the Company’s executives’ base salaries by forty percent (40%), on January 4, 2024, the Board approved certain changes to its executives’ compensation in order to ensure the retention of key members of management while the Company continues to pursue a potential strategic transaction or, in the absence of such a transaction, to enable the Company to seek bankruptcy protection. In furtherance of the foregoing, the Board approved an increase in Oliver Schacht’s, the Company’s Chief Executive Officer, base salary to $300,000 from $244,800.

 

In addition, on January 8, 2024, the Company entered into consulting agreements (each, a “Consulting Agreement”) with each of Albert Weber and Johannes Bacher, pursuant to which Mr. Weber and Mr. Bacher will continue to serve as the Chief Financial Officer and Chief Operating Officer of the Company, respectively. While Mr. Weber and Mr. Bacher are currently employed by the Company’s subsidiary Curetis GmbH (“Curetis”), as a result of Curetis’ previously disclosed insolvency proceedings, the Company agreed to enter into the Consulting Agreements in order to ensure Mr. Weber and Mr. Bacher continue to be compensated at the currently contemplated amounts. The Consulting Agreements provide that each of Mr. Weber and Mr. Bacher will receive compensation of $25,000 per month (or $300,000 on an annualized basis) commencing in January 2024. Under the Consulting Agreements, the Company also agreed to pay each of Mr. Weber and Mr. Bacher an amount of $14,200 for the months of November and December 2023, which amount reflects the difference between their then-current base salaries of $180,000 and the amounts permitted to be paid to them by Curetis while it remained subject to the ongoing insolvency proceedings. The Consulting Agreements provide that the Company will reimburse the executives for approved out-of-pocket expenses incurred in performing services for the Company.

 

The Consulting Agreements continue for a term of six months and may be terminated earlier by either the Company or the applicable executive upon thirty (30) days prior written notice. The Consulting Agreements contain other customary representations, warranties and covenants of the executives.

 

The foregoing description of the Consulting Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreements, which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

 Description 
10.1

Consulting Agreement, dated January 8, 2024, by and between OpGen, Inc. and Albert Weber.

10.2 Consulting Agreement, dated January 8, 2024, by and between OpGen, Inc. and Johannes Bacher.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 
 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

             
Date: January 9, 2024 OpGen, Inc.
       
    By:  

/s/ Oliver Schacht

        Name:   Oliver Schacht, Ph.D.
        Title:   Chief Executive Officer

 

 EX-10.1 2 ex10x1.htm CONSULTING AGREEMENT, DATED JANUARY 8, 2024, BY AND BETWEEN OPGEN, INC. AND ALBERT WEBER

Exhibit 10.1

 

 

9717 Key West Avenue, Suite 100

Rockville, MD 20850

Phone 301-869-9683

Website www.OpGen.com

 

 

Consultant Name/Entity

 

 Albert Weber

OpGen Manager

 

 Oliver Schacht

Effective Date

 

 January 8, 2024

 

CONSULTING AGREEMENT

 

This Consulting Agreement (together with its attachments, this “Agreement”) is entered into and effective as of the date written above (the “Effective Date”) by and between OpGen, Inc. a Delaware corporation having an address at 9717 Key West Avenue, Suite 100, Rockville, MD, 20850 (“OpGen”), and the consultant named above and on the signature page (“Consultant”). OpGen desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide Consulting Services (defined below) to OpGen, all as provided in this Agreement.

 

1.       Consulting Services. OpGen retains Consultant and Consultant agrees to provide Consulting Services to OpGen, including without limitation, serving as the chief financial officer of OpGen (the “Consulting Services”), as it may from time to time reasonably request and as specified in the business terms exhibit attached to this Agreement (“Business Terms Exhibit”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed upon in writing between Consultant and OpGen prior to commencement of the changes.

 

1.1   Performance. Consultant agrees to render the Consulting Services to OpGen, or to its designee, (i) at such reasonably convenient times and places as OpGen may direct, (ii) under the general supervision of OpGen, and (iii) on a best efforts basis. Consultant will comply with all rules, procedures and standards promulgated from time to time by OpGen with regard to Consultant’s access to and use of OpGen’s property, information, equipment and facilities. Consultant agrees to furnish OpGen with written reports with respect to the Consulting Services if and when requested by OpGen.

 

1.2   Third Party Confidential Information. Consultant agrees not to use any trade secrets or other confidential information of any other person, firm, corporation, institution or other entity in connection with any of the Consulting Services.

 

1.3   No Conflicts. Consultant is under no contractual or other obligation or restriction which is inconsistent with Consultant’s execution of this Agreement or the performance of the Consulting Services. During the Term (defined below), Consultant will not enter into any agreement, either written or oral, in conflict with Consultant’s obligations under this Agreement. Consultant will arrange to provide the Consulting Services in such manner and at such times that the Consulting Services will not conflict with Consultant’s responsibilities under any other agreement, arrangement or understanding or pursuant to any employment relationship Consultant has at any time with any third party.

 

1.4   Compliance with Policies. Consultant agrees to comply with all of the Company’s policies and standards, as the Company may adopt from time to time, that are applicable to the Consultant, including without limitation, code of ethics and business conduct and insider trading policies.

 

1.5   Absence of Debarment and other Disqualification. Consultant agrees and represents that neither Consultant nor any Consultant Personnel (defined below) has (have) been debarred, and to the best of Consultant’s knowledge, is (are) not under consideration to be debarred, by the U.S. Food and Drug Administration from working in or providing consulting services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992.

 

 
 

 

 

 

1.6   Other Representations and Warranties. Consultant represents and warrants that: (i) Consultant has full right and power to enter into and perform this Agreement without the consent of any third party; (ii) Consultant will comply with all laws and regulations applicable to Consultant’s obligations under this Agreement, will refrain from any unethical conduct, and will maintain high standards of professionalism; and (ii) should OpGen permit Consultant to use any of OpGen’s equipment, or facilities during the term of this Agreement, such permission shall be gratuitous and Consultant (a) shall be responsible for any injury to any person (including death) or damage to property arising out of use of such equipment or facilities; and (b) shall perform all services during OpGen’s normal business hours, unless OpGen otherwise specifically requests.

 

2.       Compensation. In consideration for the Consulting Services rendered by Consultant to OpGen, OpGen agrees to pay Consultant the fees set forth in the Business Terms Exhibit attached hereto. Unless otherwise specified in the Business Terms Exhibit, undisputed payments will be made by OpGen within thirty (30) days from OpGen’s receipt of Consultant’s complete invoice. Invoices will contain such detail as OpGen may reasonably require and will be payable in U.S. Dollars in accordance with the terms of the Business Terms Exhibit. OpGen will reimburse Consultant for reasonable and documented business expenses incurred by Consultant in the performance of the Consulting Services as specified in the Business Terms Exhibit.

 

3.       Inventions.

 

3.1   Definition. “Inventions” means all inventions, discoveries, improvements, ideas, designs, processes, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, research and creations (whether or not patentable or subject to copyright or trade secret protection) that Consultant makes, conceives or reduces to practice, either alone or jointly with others, and that (i) result from the performance of the Consulting Services, and/or (ii) result from use of facilities, equipment, supplies, Research Materials (defined below), or Confidential Information (defined below) of OpGen.

 

3.2   Ownership. Consultant will promptly disclose all Inventions in confidence to OpGen. All Inventions will be the exclusive property of OpGen. For purposes of the copyright laws of the United States, all Inventions will constitute “works made for hire”, except to the extent such Inventions cannot by law be works made for hire. To the extent Inventions have not been previously assigned to OpGen, Consultant hereby assigns and, to the extent any such assignment cannot be made at present, hereby agrees to assign to OpGen, without further compensation, all right, title and interest in and to all Inventions and any and all related patents, patent applications, copyrights, copyright applications, trademarks, trade names, trade secrets and other proprietary rights in the United States and throughout the world. Consultant retains no rights to use the Inventions and agrees not to challenge the validity of OpGen’s ownership in the Inventions. If Consultant has any right to the Inventions that cannot be assigned to OpGen by Consultant, Consultant unconditionally and irrevocably grants to OpGen during the term of such rights, an exclusive, even as to Consultant, irrevocable, perpetual, worldwide, fully paid and royalty-free license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform and publicly display in any form or medium, whether now known or later developed, make, use, sell, import, offer for sale and exercise any and all such rights. If Consultant has any rights to the Inventions that cannot be assigned or licensed to OpGen, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any kind against OpGen, an OpGen affiliate or licensee or related to OpGen’s customers, with respect to such rights, and agrees, at OpGen’s request and expense, to consent to and join in any action to enforce such rights.

 

 
 

 

 

 

3.3   Assistance. Consultant agrees to assist OpGen in every way, both during and after the term of this Agreement, to obtain and enforce United States and foreign intellectual property rights relating to Inventions in all countries. In the event OpGen is unable to secure Consultant’s signature on any document needed in connection with such purposes, Consultant hereby irrevocably designates and appoints OpGen and its duly authorized officers and agents as its agent and attorney in fact, which appointment is coupled with an interest, to act on its behalf to execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as if executed by Consultant.

 

3.4   Research Materials. For Consulting Services which involve laboratory work or experiments, “Research Materials” means all materials (i) furnished by OpGen, (ii) developed by Consultant in connection with the Consulting Services, or (iii) the cost of which are reimbursed to Consultant by OpGen. Research Materials include, in the case of biological materials, all progeny and unmodified derivatives of those materials, and in the case of chemical materials, all analogs, formulations, mixtures and compositions of those materials. Research Materials are the sole property of OpGen. Consultant agrees not to use or evaluate Research Materials for any purpose other than as directed by OpGen, nor transfer the Research Materials to any third party without the prior consent of OpGen. Consultant will use the Research Materials in compliance with all laws and regulations.

 

3.5   Records. Consultant shall make and maintain adequate and current written records of all Inventions, which records shall be available to and remain the property of OpGen at all times.

 

3.6   Agreement with Institution. This Agreement is made subject to the understanding that Consultant, if affiliated with an Institution, may be required to fulfill certain obligations, including teaching, directing laboratory operations, conducting research, and publishing work. It is further understood that Consultant may have signed an agreement concerning inventions with Institution, under which Consultant may be obligated to assign to Institution certain inventions which arise out of or otherwise relate to Consultant’s work at or for Institution or from Consultant’s use of certain of its facilities or intellectual property. In performing the Consulting Services, Consultant agrees not to utilize Institution facilities or intellectual property if the result of such use is that any Inventions will not be assignable solely to OpGen. Use of Institution’s telephone, fax machines or computers for communication purposes, however, will not constitute use of Institution’s facilities under this Agreement.

 

3.7   Work at Third Party Facilities. Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment or other resources of a third party in performing the Consulting Services nor take any other action that would result in a third party owning or having a right in any Inventions, unless agreed upon in writing in advance by OpGen.

 

4.       Confidential Information.

 

4.1   Definition. “Confidential Information” means any and all information disclosed by OpGen to Consultant, or otherwise obtained by Consultant pursuant to services provided under this Agreement that is not generally known in the Consultant’s trade or industry and shall include, without limitation, information with respect to the facilities and methods of OpGen, Research Materials, trade secrets, Inventions, systems, patents and patent applications, procedures, manuals, confidential reports, financial information, business plans, prospects, or opportunities, personnel information, lists of customers and suppliers, and information of third parties provided by OpGen to Consultant. Confidential Information does not include information which (i) is in the public domain or which becomes part of the public domain through no wrongful act on Consultant’s part but only after it becomes so publicly known, (ii) is already in Consultant’s possession at the time of disclosure by OpGen, other than by previous disclosure by OpGen, as evidenced by written or electronic records, or (iii) that becomes known to Consultant through disclosure by a third party having the right to disclose the information, as evidenced by written or electronic records.

 

 
 

 

 

 

 

4.2   Obligations of Confidentiality. Consultant will not directly or indirectly publish, disseminate or otherwise disclose, use for Consultant’s own benefit or for the benefit of a third party, deliver or make available to any third party, any Confidential Information, other than in furtherance of the purposes of this Agreement, and only then with the prior written consent of OpGen. If required, Consultant may disclose the Confidential Information to a governmental authority or by order of a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for like material and reasonable advance notice is given to OpGen. Consultant will exercise all reasonable precautions to physically protect the integrity and confidentiality of the Confidential Information and will not remove any Confidential Information or copies thereof from OpGen’s premises except to the extent necessary to fulfill the Consulting Services, and then only with OpGen’s prior consent. Consultant may disseminate or permit access to Confidential Information only to Consultant Personnel who have a need to know such Confidential Information in the course of the performance of their duties under this Agreement and who are bound to protect the confidentiality of the Confidential Information consistent with the terms of this Agreement. OpGen will be entitled to seek injunctive relief as a remedy for any breach of the terms of this Section 4.

 

5.       Restrictions. While Consultant is engaged by OpGen and for a period of eighteen (18) months after the termination or cessation of the engagement for any reason, Consultant will not (i) provide consulting services to any business or entity developing a product or sponsoring a project which competes with a product being developed or project being sponsored by OpGen and for which Consultant is providing Consulting Services. It will not be considered a competitive activity for Consultant to be a member of the faculty or staff of a university, college or other educational or non-profit research institution, nor (ii) recruit, solicit or hire any consultants of OpGen or any person who was a consultant of OpGen during the twelve (12) month period prior to the termination of Consultant’s engagement by OpGen, or induce or attempt to induce any of OpGen’s employees to terminate their employment with, or otherwise cease their relationship with, OpGen or accept employment with anyone else.

 

6.       Publication. Consultant agrees to submit to OpGen a copy of any proposed manuscript or other materials to be published or otherwise publicly disclosed which contain information or any discussion relating to OpGen or the Consulting Services, in sufficient time in advance of such disclosure, to enable OpGen to determine if patentable Inventions or any Confidential Information of OpGen would be disclosed. Consultant will cooperate with OpGen in this respect and will delete from the manuscript or other disclosure any Confidential Information if requested by OpGen, and will assist OpGen in filing for patent protection for any patentable Inventions prior to publication or other disclosure.

 

7.       Term and Termination.

 

7.1   Term. This Agreement will commence on the Effective Date and continue for the term specified on the Business Terms Exhibit (the “Term”), unless sooner terminated pursuant to the express terms of this Section 7 or extended by mutual agreement of the parties.

 

7.2   Termination. Any party may terminate this Agreement at any time without cause upon thirty (30) days’ prior written notice.

 

7.3   Termination for Breach. If either party breaches in any material respect any of its material obligations under this Agreement, in addition to any other right or remedy the non-breaching party may have, the non-breaching party may (i) terminate this Agreement effective immediate if the breach was not cured within fifteen (15) days after receipt of written notice of the breach or (ii) immediately at any time upon written notice in the event of a material breach which cannot be cured (i.e. breach of confidentiality obligation).

 

7.4   Effect of Expiration/Termination. Upon expiration or termination, neither OpGen nor Consultant will have any further obligations under this Agreement, except (i) the liabilities accrued through the date of termination, and (ii) the obligations under sections 3, 4, 5, 6, 7 and 8 will survive. Upon expiration or termination, and in any case upon OpGen’s request, Consultant will at the sole discretion of OpGen either destroy or return immediately to OpGen all tangible Confidential Information, including all copies and reproductions thereof, except for one (1) copy which may be retained solely for archival purposes.

 

 
 

 

 

 

8.       Miscellaneous.

 

8.1   Independent Contractor. All Consulting Services will be rendered by Consultant as an independent contractor and this Agreement does not create an employer-employee relationship between OpGen and Consultant. Consultant will have no rights to receive any employee benefits, such as health and accident insurance, sick leave or vacation which are accorded to regular OpGen employees. Consultant will not in any way represent himself to be an employee, partner, joint venturer, or agent of OpGen. Consultant is not authorized to make any representation, contract, or commitment on behalf of OpGen.

8.2   Taxes. Consultant will pay all required taxes on Consultant’s income from OpGen under this Agreement. Consultant agrees to accept exclusive liability for complying with all applicable state and federal laws, including laws governing self-employed individuals, if applicable, such as laws related to payment of taxes, social security, disability, and other contributions based on fees paid to Consultant under this Agreement. OpGen will not withhold or make payments for social security, unemployment insurance or disability insurance contributions, or obtain workers’ compensation insurance on Consultant’s behalf. Consultant will provide OpGen with Consultant’s taxpayer identification number or social security number, as applicable.

8.3   Use of Name. Consultant consents to the use by OpGen of Consultant’s name and likeness in written materials and oral presentations to current or prospective customers, partners, investors or others, provided that such materials or presentations accurately describe the nature of Consultant’s relationship with or contribution to OpGen.

8.4   Assignability and Binding Effect. The Consulting Services to be rendered by Consultant are personal in nature. Consultant may not assign or transfer this Agreement or any of Consultant’s rights or obligations hereunder except to a corporation of which Consultant is the sole stockholder. In no event will Consultant assign or delegate responsibility for actual performance of the Consulting Services to any other natural person except to Consultant Personnel as provided for under this Agreement. This Agreement will be binding upon and inure to the benefit of the parties and their respective legal representatives, heirs, successors and permitted assigns. OpGen may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger, consolidation or otherwise) all or substantially all of the business and/or assets of OpGen.

 

8.5   Headings. The section headings are included solely for convenience of reference and will not control or affect the meaning or interpretation of any of the provisions of this Agreement.

8.6   Notices. Any notices or other communications from one party to the other will be in writing and will be given by addressing the same to the other at the address or facsimile number set forth in this Agreement. Notices to OpGen will be marked “Attention: Chief Executive Officer”. Notice will be deemed to have been duly given when (i) deposited in the United States mail with proper postage for first class registered or certified mail prepaid, return receipt requested, (ii sent by any reputable commercial courier, delivery confirmation requested, (iii) delivered personally, or (iv) if promptly confirmed by mail or commercial courier as provided above, when dispatched by facsimile.

 

8.7   No Modification. This Agreement may be changed only by a writing signed by authorized representatives of both parties.

 

8.8   Severability. In the event that any one or more of the provisions contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and all other provisions will remain in full force and effect. If any provision of this Agreement is held to be excessively broad, it will be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law.

 

 
 

 

 

 

8.9   Entire Agreement. This Agreement constitutes the entire agreement of the parties with regard to its subject matter, and supersedes all previous written or oral representations, agreements and understandings between the parties.

 

8.10  Governing Law. This Agreement will be governed by, and construed and enforced in accordance with, the laws of the Federal Republic of Germany applicable to contracts made and to be performed therein, without giving effect to the principles thereof relating to the conflict of laws.

 

8.11  Remedies. Consultant agrees that in addition to any other rights and remedies available to OpGen for any breach or threatened breach by Consultant of Consultant’s obligations hereunder, OpGen will be entitled to enforcement of Consultant’s obligations hereunder by whatever means are at OpGen’s disposal, including court injunction.

 

8.12  Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

 

- Signatures on next page –

 

 
 

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement under seal as of the Effective Date.

 

OpGen, Inc.

Consultant/Entity:

 

/s/ William Rhodes

__________________________________________

Signature:

 

/s/ Albert Weber

__________________________________________

Signature:

 

William Rhodes, Chairman Printed Name: Albert Weber

 

 

/s/ Oliver Schacht

_________________________________________

Signature:

 

Oliver Schacht, President & CEO

  

 

January 8, 2024

__________________________________________

Date

 

January 8, 2024

__________________________________________

Date

 

 

 

Address: [**]

 

________________________________________

Mobile:

 

[**]

__________________________________________

 

 

Facimile: NA

 

 

   

 

 
 

 

 

 

INSTITUTION ACKNOWLEDGEMENT
AND CONSENT FORM

 

OpGen, Inc. (“OpGen”) is prepared to enter into the foregoing Agreement with the consultant named on the preceding signature page (“Consultant”). OpGen recognizes that as a member of the institution named below (“Institution”), Consultant is responsible for ensuring that any consulting agreement Consultant enters into with a for-profit entity is not in conflict with the patent, consulting or other policies of Institution. The proposed Agreement requires Consultant, if required by Institution policies, to disclose the proposed Agreement to Institution and/or to obtain Institution’s consent to enter into the proposed Agreement.

Institution hereby acknowledges and consents to Consultant entering into the foregoing Agreement.

INSTITUTION:

 

By ____________________

Print Name ____________________

Title ____________________

Date ____________________

 

 

 

 EX-10.2 3 ex10x2.htm CONSULTING AGREEMENT, DATED JANUARY 8, 2024, BY AND BETWEEN OPGEN, INC. AND JOHANNES BACHER.

Exhibit 10.2

 

 

 

9717 Key West Avenue, Suite 100

Rockville, MD 20850

Phone 301-869-9683

Website www.OpGen.com

 

 

 

Consultant Name/Entity

 

 Johannes Bacher

OpGen Manager

 

 Oliver Schacht

Effective Date

 

 January 8, 2024

 

CONSULTING AGREEMENT

 

This Consulting Agreement (together with its attachments, this “Agreement”) is entered into and effective as of the date written above (the “Effective Date”) by and between OpGen, Inc. a Delaware corporation having an address at 9717 Key West Avenue, Suite 100, Rockville, MD, 20850 (“OpGen”), and the consultant named above and on the signature page (“Consultant”). OpGen desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide Consulting Services (defined below) to OpGen, all as provided in this Agreement.

 

1.       Consulting Services. OpGen retains Consultant and Consultant agrees to provide Consulting Services to OpGen, including without limitation, serving as the chief operating officer of OpGen (the “Consulting Services”), as it may from time to time reasonably request and as specified in the business terms exhibit attached to this Agreement (“Business Terms Exhibit”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed upon in writing between Consultant and OpGen prior to commencement of the changes.

 

1.1   Performance. Consultant agrees to render the Consulting Services to OpGen, or to its designee, (i) at such reasonably convenient times and places as OpGen may direct, (ii) under the general supervision of OpGen, and (iii) on a best efforts basis. Consultant will comply with all rules, procedures and standards promulgated from time to time by OpGen with regard to Consultant’s access to and use of OpGen’s property, information, equipment and facilities. Consultant agrees to furnish OpGen with written reports with respect to the Consulting Services if and when requested by OpGen.

 

1.2   Third Party Confidential Information. Consultant agrees not to use any trade secrets or other confidential information of any other person, firm, corporation, institution or other entity in connection with any of the Consulting Services.

 

1.3   No Conflicts. Consultant is under no contractual or other obligation or restriction which is inconsistent with Consultant’s execution of this Agreement or the performance of the Consulting Services. During the Term (defined below), Consultant will not enter into any agreement, either written or oral, in conflict with Consultant’s obligations under this Agreement. Consultant will arrange to provide the Consulting Services in such manner and at such times that the Consulting Services will not conflict with Consultant’s responsibilities under any other agreement, arrangement or understanding or pursuant to any employment relationship Consultant has at any time with any third party.

 

1.4   Compliance with Policies. Consultant agrees to comply with all of the Company’s policies and standards, as the Company may adopt from time to time, that are applicable to the Consultant, including without limitation, code of ethics and business conduct and insider trading policies.

 

1.5   Absence of Debarment and other Disqualification. Consultant agrees and represents that neither Consultant nor any Consultant Personnel (defined below) has (have) been debarred, and to the best of Consultant’s knowledge, is (are) not under consideration to be debarred, by the U.S. Food and Drug Administration from working in or providing consulting services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992.

 

 
 

 

 

 

1.6   Other Representations and Warranties. Consultant represents and warrants that: (i) Consultant has full right and power to enter into and perform this Agreement without the consent of any third party; (ii) Consultant will comply with all laws and regulations applicable to Consultant’s obligations under this Agreement, will refrain from any unethical conduct, and will maintain high standards of professionalism; and (ii) should OpGen permit Consultant to use any of OpGen’s equipment, or facilities during the term of this Agreement, such permission shall be gratuitous and Consultant (a) shall be responsible for any injury to any person (including death) or damage to property arising out of use of such equipment or facilities; and (b) shall perform all services during OpGen’s normal business hours, unless OpGen otherwise specifically requests.

 

2.       Compensation. In consideration for the Consulting Services rendered by Consultant to OpGen, OpGen agrees to pay Consultant the fees set forth in the Business Terms Exhibit attached hereto. Unless otherwise specified in the Business Terms Exhibit, undisputed payments will be made by OpGen within thirty (30) days from OpGen’s receipt of Consultant’s complete invoice. Invoices will contain such detail as OpGen may reasonably require and will be payable in U.S. Dollars in accordance with the terms of the Business Terms Exhibit. OpGen will reimburse Consultant for reasonable and documented business expenses incurred by Consultant in the performance of the Consulting Services as specified in the Business Terms Exhibit.

 

3.       Inventions.

 

3.1   Definition. “Inventions” means all inventions, discoveries, improvements, ideas, designs, processes, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, research and creations (whether or not patentable or subject to copyright or trade secret protection) that Consultant makes, conceives or reduces to practice, either alone or jointly with others, and that (i) result from the performance of the Consulting Services, and/or (ii) result from use of facilities, equipment, supplies, Research Materials (defined below), or Confidential Information (defined below) of OpGen.

 

3.2   Ownership. Consultant will promptly disclose all Inventions in confidence to OpGen. All Inventions will be the exclusive property of OpGen. For purposes of the copyright laws of the United States, all Inventions will constitute “works made for hire”, except to the extent such Inventions cannot by law be works made for hire. To the extent Inventions have not been previously assigned to OpGen, Consultant hereby assigns and, to the extent any such assignment cannot be made at present, hereby agrees to assign to OpGen, without further compensation, all right, title and interest in and to all Inventions and any and all related patents, patent applications, copyrights, copyright applications, trademarks, trade names, trade secrets and other proprietary rights in the United States and throughout the world. Consultant retains no rights to use the Inventions and agrees not to challenge the validity of OpGen’s ownership in the Inventions. If Consultant has any right to the Inventions that cannot be assigned to OpGen by Consultant, Consultant unconditionally and irrevocably grants to OpGen during the term of such rights, an exclusive, even as to Consultant, irrevocable, perpetual, worldwide, fully paid and royalty-free license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform and publicly display in any form or medium, whether now known or later developed, make, use, sell, import, offer for sale and exercise any and all such rights. If Consultant has any rights to the Inventions that cannot be assigned or licensed to OpGen, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any kind against OpGen, an OpGen affiliate or licensee or related to OpGen’s customers, with respect to such rights, and agrees, at OpGen’s request and expense, to consent to and join in any action to enforce such rights.

 

3.3   Assistance. Consultant agrees to assist OpGen in every way, both during and after the term of this Agreement, to obtain and enforce United States and foreign intellectual property rights relating to Inventions in all countries. In the event OpGen is unable to secure Consultant’s signature on any document needed in connection with such purposes, Consultant hereby irrevocably designates and appoints OpGen and its duly authorized officers and agents as its agent and attorney in fact, which appointment is coupled with an interest, to act on its behalf to execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as if executed by Consultant.

 

 
 

 

 

3.4   Research Materials. For Consulting Services which involve laboratory work or experiments, “Research Materials” means all materials (i) furnished by OpGen, (ii) developed by Consultant in connection with the Consulting Services, or (iii) the cost of which are reimbursed to Consultant by OpGen. Research Materials include, in the case of biological materials, all progeny and unmodified derivatives of those materials, and in the case of chemical materials, all analogs, formulations, mixtures and compositions of those materials. Research Materials are the sole property of OpGen. Consultant agrees not to use or evaluate Research Materials for any purpose other than as directed by OpGen, nor transfer the Research Materials to any third party without the prior consent of OpGen. Consultant will use the Research Materials in compliance with all laws and regulations.

 

3.5   Records. Consultant shall make and maintain adequate and current written records of all Inventions, which records shall be available to and remain the property of OpGen at all times.

 

3.6   Agreement with Institution. This Agreement is made subject to the understanding that Consultant, if affiliated with an Institution, may be required to fulfill certain obligations, including teaching, directing laboratory operations, conducting research, and publishing work. It is further understood that Consultant may have signed an agreement concerning inventions with Institution, under which Consultant may be obligated to assign to Institution certain inventions which arise out of or otherwise relate to Consultant’s work at or for Institution or from Consultant’s use of certain of its facilities or intellectual property. In performing the Consulting Services, Consultant agrees not to utilize Institution facilities or intellectual property if the result of such use is that any Inventions will not be assignable solely to OpGen. Use of Institution’s telephone, fax machines or computers for communication purposes, however, will not constitute use of Institution’s facilities under this Agreement.

 

3.7   Work at Third Party Facilities. Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment or other resources of a third party in performing the Consulting Services nor take any other action that would result in a third party owning or having a right in any Inventions, unless agreed upon in writing in advance by OpGen.

 

4.       Confidential Information.

 

4.1   Definition. “Confidential Information” means any and all information disclosed by OpGen to Consultant, or otherwise obtained by Consultant pursuant to services provided under this Agreement that is not generally known in the Consultant’s trade or industry and shall include, without limitation, information with respect to the facilities and methods of OpGen, Research Materials, trade secrets, Inventions, systems, patents and patent applications, procedures, manuals, confidential reports, financial information, business plans, prospects, or opportunities, personnel information, lists of customers and suppliers, and information of third parties provided by OpGen to Consultant. Confidential Information does not include information which (i) is in the public domain or which becomes part of the public domain through no wrongful act on Consultant’s part but only after it becomes so publicly known, (ii) is already in Consultant’s possession at the time of disclosure by OpGen, other than by previous disclosure by OpGen, as evidenced by written or electronic records, or (iii) that becomes known to Consultant through disclosure by a third party having the right to disclose the information, as evidenced by written or electronic records.

 

 

 
 

 

 

 

4.2   Obligations of Confidentiality. Consultant will not directly or indirectly publish, disseminate or otherwise disclose, use for Consultant’s own benefit or for the benefit of a third party, deliver or make available to any third party, any Confidential Information, other than in furtherance of the purposes of this Agreement, and only then with the prior written consent of OpGen. If required, Consultant may disclose the Confidential Information to a governmental authority or by order of a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for like material and reasonable advance notice is given to OpGen. Consultant will exercise all reasonable precautions to physically protect the integrity and confidentiality of the Confidential Information and will not remove any Confidential Information or copies thereof from OpGen’s premises except to the extent necessary to fulfill the Consulting Services, and then only with OpGen’s prior consent. Consultant may disseminate or permit access to Confidential Information only to Consultant Personnel who have a need to know such Confidential Information in the course of the performance of their duties under this Agreement and who are bound to protect the confidentiality of the Confidential Information consistent with the terms of this Agreement. OpGen will be entitled to seek injunctive relief as a remedy for any breach of the terms of this Section 4.

 

5.       Restrictions. While Consultant is engaged by OpGen and for a period of eighteen (18) months after the termination or cessation of the engagement for any reason, Consultant will not (i) provide consulting services to any business or entity developing a product or sponsoring a project which competes with a product being developed or project being sponsored by OpGen and for which Consultant is providing Consulting Services. It will not be considered a competitive activity for Consultant to be a member of the faculty or staff of a university, college or other educational or non-profit research institution, nor (ii) recruit, solicit or hire any consultants of OpGen or any person who was a consultant of OpGen during the twelve (12) month period prior to the termination of Consultant’s engagement by OpGen, or induce or attempt to induce any of OpGen’s employees to terminate their employment with, or otherwise cease their relationship with, OpGen or accept employment with anyone else.

 

6.       Publication. Consultant agrees to submit to OpGen a copy of any proposed manuscript or other materials to be published or otherwise publicly disclosed which contain information or any discussion relating to OpGen or the Consulting Services, in sufficient time in advance of such disclosure, to enable OpGen to determine if patentable Inventions or any Confidential Information of OpGen would be disclosed. Consultant will cooperate with OpGen in this respect and will delete from the manuscript or other disclosure any Confidential Information if requested by OpGen, and will assist OpGen in filing for patent protection for any patentable Inventions prior to publication or other disclosure.

 

7.       Term and Termination.

 

7.1   Term. This Agreement will commence on the Effective Date and continue for the term specified on the Business Terms Exhibit (the “Term”), unless sooner terminated pursuant to the express terms of this Section 7 or extended by mutual agreement of the parties.

 

7.2   Termination. Any party may terminate this Agreement at any time without cause upon thirty (30) days’ prior written notice.

 

7.3   Termination for Breach. If either party breaches in any material respect any of its material obligations under this Agreement, in addition to any other right or remedy the non-breaching party may have, the non-breaching party may (i) terminate this Agreement effective immediate if the breach was not cured within fifteen (15) days after receipt of written notice of the breach or (ii) immediately at any time upon written notice in the event of a material breach which cannot be cured (i.e. breach of confidentiality obligation).

 

7.4   Effect of Expiration/Termination. Upon expiration or termination, neither OpGen nor Consultant will have any further obligations under this Agreement, except (i) the liabilities accrued through the date of termination, and (ii) the obligations under sections 3, 4, 5, 6, 7 and 8 will survive. Upon expiration or termination, and in any case upon OpGen’s request, Consultant will at the sole discretion of OpGen either destroy or return immediately to OpGen all tangible Confidential Information, including all copies and reproductions thereof, except for one (1) copy which may be retained solely for archival purposes.

 

 
 

 

 

 

8.       Miscellaneous.

 

8.1   Independent Contractor. All Consulting Services will be rendered by Consultant as an independent contractor and this Agreement does not create an employer-employee relationship between OpGen and Consultant. Consultant will have no rights to receive any employee benefits, such as health and accident insurance, sick leave or vacation which are accorded to regular OpGen employees. Consultant will not in any way represent himself to be an employee, partner, joint venturer, or agent of OpGen. Consultant is not authorized to make any representation, contract, or commitment on behalf of OpGen.

8.2   Taxes. Consultant will pay all required taxes on Consultant’s income from OpGen under this Agreement. Consultant agrees to accept exclusive liability for complying with all applicable state and federal laws, including laws governing self-employed individuals, if applicable, such as laws related to payment of taxes, social security, disability, and other contributions based on fees paid to Consultant under this Agreement. OpGen will not withhold or make payments for social security, unemployment insurance or disability insurance contributions, or obtain workers’ compensation insurance on Consultant’s behalf. Consultant will provide OpGen with Consultant’s taxpayer identification number or social security number, as applicable.

8.3   Use of Name. Consultant consents to the use by OpGen of Consultant’s name and likeness in written materials and oral presentations to current or prospective customers, partners, investors or others, provided that such materials or presentations accurately describe the nature of Consultant’s relationship with or contribution to OpGen.

8.4   Assignability and Binding Effect. The Consulting Services to be rendered by Consultant are personal in nature. Consultant may not assign or transfer this Agreement or any of Consultant’s rights or obligations hereunder except to a corporation of which Consultant is the sole stockholder. In no event will Consultant assign or delegate responsibility for actual performance of the Consulting Services to any other natural person except to Consultant Personnel as provided for under this Agreement. This Agreement will be binding upon and inure to the benefit of the parties and their respective legal representatives, heirs, successors and permitted assigns. OpGen may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger, consolidation or otherwise) all or substantially all of the business and/or assets of OpGen.

 

8.5   Headings. The section headings are included solely for convenience of reference and will not control or affect the meaning or interpretation of any of the provisions of this Agreement.

8.6   Notices. Any notices or other communications from one party to the other will be in writing and will be given by addressing the same to the other at the address or facsimile number set forth in this Agreement. Notices to OpGen will be marked “Attention: Chief Executive Officer”. Notice will be deemed to have been duly given when (i) deposited in the United States mail with proper postage for first class registered or certified mail prepaid, return receipt requested, (ii sent by any reputable commercial courier, delivery confirmation requested, (iii) delivered personally, or (iv) if promptly confirmed by mail or commercial courier as provided above, when dispatched by facsimile.

 

8.7   No Modification. This Agreement may be changed only by a writing signed by authorized representatives of both parties.

 

8.8   Severability. In the event that any one or more of the provisions contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and all other provisions will remain in full force and effect. If any provision of this Agreement is held to be excessively broad, it will be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law.

 

 
 

 

 

 

8.9   Entire Agreement. This Agreement constitutes the entire agreement of the parties with regard to its subject matter, and supersedes all previous written or oral representations, agreements and understandings between the parties.

 

8.10  Governing Law. This Agreement will be governed by, and construed and enforced in accordance with, the laws of the Federal Republic of Germany applicable to contracts made and to be performed therein, without giving effect to the principles thereof relating to the conflict of laws.

 

8.11  Remedies. Consultant agrees that in addition to any other rights and remedies available to OpGen for any breach or threatened breach by Consultant of Consultant’s obligations hereunder, OpGen will be entitled to enforcement of Consultant’s obligations hereunder by whatever means are at OpGen’s disposal, including court injunction.

 

8.12  Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

 

- Signatures on next page –

 

 
 

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement under seal as of the Effective Date.

 

OpGen, Inc.

Consultant/Entity:

 

 

/s/ William Rhodes

__________________________________________

Signature:

 

/s/ Johannes Bacher

__________________________________________

Signature:

 

William Rhodes, Chairman Printed Name: Johannes Bacher

 

 

/s/ Oliver Schacht

_________________________________________

Signature:

 

Oliver Schacht, President & CEO

  

 

January 8, 2024

__________________________________________

Date

 

January 8, 2024

__________________________________________

Date

 

 

 

Address: [**]

 

________________________________________

Mobile:

 

[**]

__________________________________________

 

 

Facimile: NA

 

 

 

 

 

 

 
 

 

 

 

INSTITUTION ACKNOWLEDGEMENT
AND CONSENT FORM

 

OpGen, Inc. (“OpGen”) is prepared to enter into the foregoing Agreement with the consultant named on the preceding signature page (“Consultant”). OpGen recognizes that as a member of the institution named below (“Institution”), Consultant is responsible for ensuring that any consulting agreement Consultant enters into with a for-profit entity is not in conflict with the patent, consulting or other policies of Institution. The proposed Agreement requires Consultant, if required by Institution policies, to disclose the proposed Agreement to Institution and/or to obtain Institution’s consent to enter into the proposed Agreement.

Institution hereby acknowledges and consents to Consultant entering into the foregoing Agreement.

INSTITUTION:

 

By ____________________

Print Name ____________________

Title ____________________

Date ____________________

 

 

 GRAPHIC 4 image_001.jpg GRAPHIC begin 644 image_001.jpg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image_002.gif GRAPHIC begin 644 image_002.gif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�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end EX-101.SCH 6 opgn-20240104.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 opgn-20240104_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 opgn-20240104_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 04, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 04, 2024
Entity File Number 001-37367
Entity Registrant Name OpGen, Inc.
Entity Central Index Key 0001293818
Entity Tax Identification Number 06-1614015
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9717 Key West Ave
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 240
Local Phone Number 813-1260
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OPGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 opgen_8k_htm.xml IDEA: XBRL DOCUMENT 0001293818 2024-01-04 2024-01-04 iso4217:USD shares iso4217:USD shares false 0001293818 8-K 2024-01-04 OpGen, Inc. DE 001-37367 06-1614015 9717 Key West Ave Suite 100 Rockville MD 20850 240 813-1260 false false false false Common Stock OPGN NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://opgen.com/role/Cover Cover Cover 1 false false All Reports Book All Reports opgen_8k.htm opgn-20240104.xsd opgn-20240104_lab.xml opgn-20240104_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "opgen_8k.htm": { "nsprefix": "OPGN", "nsuri": "http://opgen.com/20240104", "dts": { "inline": { "local": [ "opgen_8k.htm" ] }, "schema": { "local": [ "opgn-20240104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "opgn-20240104_lab.xml" ] }, "presentationLink": { "local": [ "opgn-20240104_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://opgen.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "opgen_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "opgen_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://opgen.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001079973-24-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-24-000043-xbrl.zip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end